YUNG SHIN PHARM. IND. CO., LTD.

🇹🇼Taiwan

Country: 🇹🇼Taiwan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Parecoxib After Intravenous Bolus of Parecoxib in Healthy Volunteers Under Fasting Conditions

Phase 4

Not yet recruiting

Conditions: Post-operative Pain
Bioequivalence Study in Healthy Subjects

Interventions: Drug: Parecoxib

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 14

Registration Number: NCT06600282

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer

Phase 2

Terminated

Conditions: Hot Flashes
Breast Cancer

Interventions: Drug: 0.8 mg RCN3028
Drug: Placebo

First Posted Date: 2023-12-08

Last Posted Date: 2023-12-08

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 10

Registration Number: NCT06161792

Locations: 🇨🇳
Taipei Medical University Hospital, Taipei, Taiwan
🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

and more 1 locations

Evaluate Bioequivalence of Burotam (1/1 g/Vial)

Phase 4

Conditions: Infectious Diseases

Interventions: Drug: cefoperazone sodium and sulbactam sodium

First Posted Date: 2022-12-16

Last Posted Date: 2023-02-01

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 14

Registration Number: NCT05654090

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

Evaluate Bioequivalence of Micafungin (50mg/Vial)

Phase 4

Completed

Conditions: Invasive Candidiasis

Interventions: Drug: Micafungin

First Posted Date: 2022-08-11

Last Posted Date: 2022-08-11

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 14

Registration Number: NCT05496725

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

Evaluate the Efficacy and Safety of Lidocaine-Containing Hyaluronic Acid Filler in the Treatment of Nasolabial Folds.

Not Applicable

Completed

Conditions: Wrinkles Such as Nasolabial Folds

Interventions: Device: PavéDerm J-Fill Soft Dermal Filler
Device: Restylane® Lyft Lidocaine

First Posted Date: 2021-09-10

Last Posted Date: 2021-09-10

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT05040594

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan

Pharmacokinetics of Two Formulation of Tenofovir Disoproxil Fumarate

Phase 4

Completed

Conditions: Pharmacokinetic of Tenofovir in Healthy Subjects

Interventions: Drug: Tenofovir Disoproxil Fumarate 300 MG

First Posted Date: 2020-12-17

Last Posted Date: 2020-12-17

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT04671563

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)

Phase 4

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting, Prophylaxis

Interventions: Drug: Palonosetron

First Posted Date: 2020-10-14

Last Posted Date: 2021-08-04

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT04585412

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

Evaluate Bioequivalence of Voriconazole(200mg/Vial) .

Phase 4

Completed

Conditions: Antimycotic for Systematic Use

Interventions: Drug: Vaway

First Posted Date: 2020-09-17

Last Posted Date: 2020-09-17

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 14

Registration Number: NCT04552353

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

Pharmacokinetics of Nalbuphine Injection

Phase 4

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Nalbuphine

First Posted Date: 2019-02-01

Last Posted Date: 2019-02-01

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 14

Registration Number: NCT03826316

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

Pharmacokinetics of Two Formulation of Pregabalin

Phase 4

Completed

Conditions: Diabetic Peripheral Neuropathy
Fibromyalgia
Partial Seizure Disorder

Interventions: Drug: Pregabalin

First Posted Date: 2018-10-19

Last Posted Date: 2019-01-28

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT03712475

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy